

檢驗報告

報告編號： UB/2012/71195A-10 日期： 2012年08月16日 頁數： 1 of 4



神農真菌生技有限公司

桃園縣桃園市同德里中埔6街50之2號1F

以下測試之樣品係由供應廠商所提供及確認：

產品名稱： 牛樟芝濃縮萃取液
申請廠商： 神農真菌生技有限公司
送樣日期： 2012年07月30日
測試日期： 2012年07月31日
測試結果： - 請見下頁 -

Signed for and on behalf of
SGS Taiwan Ltd.

Yuan-Min Wen
Manager



Unless otherwise stated the results shown in this test report refer only to the sample(s) tested. This test report cannot be reproduced, except in full, without prior written permission of the Company. 除非另有說明，此報告結果僅對測試的樣品負責。本報告未經本公司書面許可，不可部份複製。
This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at www.sgs.com/terms_and_conditions.htm and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at www.sgs.com/terms_e-document.htm. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

檢驗報告

報告編號：

UB/2012/71195A-10

日期：2012年08月16日

頁數：2 of 4



神農真菌生技有限公司

桃園縣桃園市同德里中埔6街50之2號1F

測試結果：

測試項目	CAS NO.	測試方法	測試結果	檢測極限	單位
重金屬	---	---	---	---	---
砷 (As)	007440-38-2	本測試參考USEPA 3051方法，以感應耦合電漿光譜儀(ICP/OES) 檢測。	N.D.	2.00	ppm(mg/kg)
鉛 (Pb)	007439-92-1		N.D.	2.00	ppm(mg/kg)
汞 (Hg)	007439-97-6		N.D.	2.00	ppm(mg/kg)
鎘 (Cd)	007440-43-9		N.D.	2.00	ppm(mg/kg)
黃麴毒素	---	---	---	---	---
Aflatoxin B1	001162-65-8	本測試參考CNS 4090方法，以高效液相層析儀/螢光偵測器(HPLC/FLD) 檢測。	N.D.	0.200	ppb(µg/kg)
Aflatoxin B2	007220-81-7		N.D.	0.200	ppb(µg/kg)
Aflatoxin G1	001165-39-5		N.D.	0.200	ppb(µg/kg)
Aflatoxin G2	007241-98-7		N.D.	0.200	ppb(µg/kg)
麥角固醇(Ergosterol)	---	本測試以高效液相層析儀/二極體陣列偵測器(HPLC/DAD)檢測。	N.D.	0.0020	%(w/w)
減肥藥	---	---	---	---	---
7-Ketodehydroepiandrosterone(分子量：302.4)	---	本測試參考Journal of Pharmaceutical and Biomedical Analysis Volume 40, Issue 2, 13 February 2006, Pages 305-311，以及4.5. E.D. Drugs and Analogs, Samuel R. Gratz, Ph.D, Food and Drug Administration，以液相層析串聯質譜儀(LC/MS/MS)檢測。	N.D.	10.0	ppm(mg/kg)
N-Desmethyisibutramine(分子量：265.5)	---		N.D.	10.0	ppm(mg/kg)
N-Didesmethyisibutramine(分子量：251.5)	---		N.D.	10.0	ppm(mg/kg)
Orlistat	---		N.D.	10.0	ppm(mg/kg)
Rimonabant	---		N.D.	10.0	ppm(mg/kg)
Sibutramine	---		N.D.	10.0	ppm(mg/kg)
Synephrine	---		N.D.	10.0	ppm(mg/kg)
Sennoside A	---		N.D.	10.0	ppm(mg/kg)
Sennoside B	---		N.D.	10.0	ppm(mg/kg)

Unless otherwise stated the results shown in this test report refer only to the sample(s) tested. This test report cannot be reproduced, except in full, without prior written permission of the Company. 除非另有說明，此報告結果僅對測試的樣品負責。本報告未經本公司書面許可，不可部份複製。
This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at www.sgs.com/terms_and_conditions.htm and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at www.sgs.com/terms_e-document.htm. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

檢驗報告

報告編號：

UB/2012/71195A-10

日期：2012年08月16日

頁數：3 of 4



神農真菌生技有限公司

桃園縣桃園市同德里中埔6街50之2號1F

壯陽藥	---	---	---	---	---
2-(2-ethoxy-phenyl)-5-methyl-7-propyl-3H-imidazo(5,1-f)-(1,2,4)triazin-4-one(分子量:312)	---	本測試參考Journal of Pharmaceutical and Biomedical Analysis Volume 40, Issue 2, 13 February 2006, Pages 305-311 , 以及4.5. E.D. Drugs and Analogs, Samuel R. Gratz, Ph.D, Food and Drug Administration , 以液相層析串聯質譜儀(LC/MS/MS)檢測。	N.D.	10.0	ppm(mg/kg)
Acetil acid(分子量:356)	---		N.D.	10.0	ppm(mg/kg)
Acetildenafil(分子量:466)	---		N.D.	20.0	ppm(mg/kg)
Aminotadalafil(分子量:390)	---		N.D.	10.0	ppm(mg/kg)
Carbodenafil(分子量:452)	---		N.D.	10.0	ppm(mg/kg)
Dimethylsildenafil(分子量:488)	---		N.D.	10.0	ppm(mg/kg)
Gendenafil(分子量:354)	---		N.D.	10.0	ppm(mg/kg)
Homosildenafil(分子量:488)	---		N.D.	10.0	ppm(mg/kg)
Hydroxyacetildenafil(分子量:482)	---		N.D.	10.0	ppm(mg/kg)
Hydroxyhomosildenafil(分子量:504)	---		N.D.	10.0	ppm(mg/kg)
Hydroxythiohomosildenafil(分子量:520)	---		N.D.	10.0	ppm(mg/kg)
Piperiacetildenafil(分子量:437)	---		N.D.	10.0	ppm(mg/kg)
Pseudovardenafil(分子量:459)	---		N.D.	10.0	ppm(mg/kg)
Sildenafil	---		N.D.	10.0	ppm(mg/kg)
Tadalafil	---		N.D.	10.0	ppm(mg/kg)
Thiodimethylsildenafil(分子量:504)	---		N.D.	10.0	ppm(mg/kg)
Thiohomosildenafil(分子量:504)	---		N.D.	10.0	ppm(mg/kg)
Thiosildenafil(分子量:490)	---		N.D.	10.0	ppm(mg/kg)
Vardenafil	---		N.D.	10.0	ppm(mg/kg)
Noracetildenafil(分子量:452)	---		N.D.	10.0	ppm(mg/kg)
Nortadalafil(分子量:375.39)	---	N.D.	10.0	ppm(mg/kg)	
Sildenafil analogue (分子量:502)	---	N.D.	10.0	ppm(mg/kg)	
Sildenafil analogue (分子量:518.7)	---	N.D.	10.0	ppm(mg/kg)	
Sildenafil analogue (分子量:534.7)	---	N.D.	10.0	ppm(mg/kg)	
Sildenafil analogue (分子量:484.68)	---	N.D.	10.0	ppm(mg/kg)	
Dithio-desmethyl-carbodenafil (分子量:470.66)	---	N.D.	10.0	ppm(mg/kg)	
Chloropretadalafil(分子量:426.86)	---	N.D.	10.0	ppm(mg/kg)	

備註：1. 本報告不得分離，分離使用無效。

2. 低於方法偵測極限之測定值以 " N.D. " 表示。

- END -

Unless otherwise stated the results shown in this test report refer only to the sample(s) tested. This test report cannot be reproduced, except in full, without prior written permission of the Company. 除非另有說明，此報告結果僅對測試的樣品負責。本報告未經本公司書面許可，不可部份複製。
This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at www.sgs.com/terms_and_conditions.htm and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at www.sgs.com/terms_e-document.htm. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

檢驗報告

報告編號：

UB/2012/71195A-10

日期：2012年08月16日

頁數：4 of 4



神農真菌生技有限公司

桃園縣桃園市同德里中埔6街50之2號1F

樣品照片



Unless otherwise stated the results shown in this test report refer only to the sample(s) tested. This test report cannot be reproduced, except in full, without prior written permission of the Company. 除非另有說明，此報告結果僅對測試的樣品負責。本報告未經本公司書面許可，不可部份複製。
This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at www.sgs.com/terms_and_conditions.htm and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at www.sgs.com/terms_e-document.htm. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.